Emil Kuriakose compensation by year
Terns Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $510,000 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,541,416 |
| Non-equity incentive | $295,800 |
| Pension and deferred compensation | $0 |
| All other | $14,000 |
| Total | $2,361,216 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Terns Pharmaceuticals, Inc. 10-K/A filed April 27, 2026, accession 0001193125-26-182140, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Terns Pharmaceuticals, Inc. filed document, accession 0001193125-26-182140. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 33,047 | $1,335,099 | — |
| Option | 99,167 | — | $12.93 |
| Option | 61,198 | — | $5.46 |
| Option | 90,000 | — | $6.59 |
| Option | 485,000 | — | $4.64 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Terns Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2025 proxy (filed April 27, 2026)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-05 | Disposition to the issuer derivative | — | 485,000 | — | 0 |
| 2026-05-05 | Disposition to the issuer derivative | — | 117,500 | — | 0 |
| 2026-05-05 | Disposition to the issuer derivative | — | 120,000 | — | 0 |
| 2026-05-05 | Disposition to the issuer derivative | — | 112,500 | — | 0 |
| 2026-05-05 | Disposition to the issuer | — | 81,953 | $53.00 | 0 |
| 2026-05-05 | Disposition to the issuer derivative | — | 280,000 | — | 0 |
| 2026-05-05 | U | — | 24,562 | $53.00 | 0 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Terns Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Amy Burroughs | Chief Executive Officer and Director | $4,589,929 |
| Andrew Gengos | Chief Financial Officer and Treasurer | $2,621,738 |
| Emil Kuriakose · this page | Chief Medical Officer | $2,361,216 |
The full Terns Pharmaceuticals compensation record
free company briefThis page is one person within Terns Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Terns Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.